FEV₁ is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease

References

• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. doi:10.1183/13993003.00214-201728182564
   PubMed Web of Science ®Google Scholar
• PrudenteR, FrancoEAT, MesquitaCB, FerrariR, de GodoyI, TanniSE. Predictors of mortality in patients with COPD after 9 years. Int J Chron Obstruct Pulmon Dis. 2018;13:3389–3398. doi:10.2147/COPD.S17466530410324
   PubMed Web of Science ®Google Scholar
• SorianoJB, LamprechtB, RamirezAS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med. 2015;3(6):443–450. doi:10.1016/S2213-2600(15)00157-525995071
   PubMed Web of Science ®Google Scholar
• CelliBR, CoteCG, MarinJM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa02132214999112
   PubMed Web of Science ®Google Scholar
• GoossensLM, LeimerI, MetzdorfN, BeckerK, Rutten-van MolkenMP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014;14:163. doi:10.1186/1471-2466-14-16325326750
   PubMed Web of Science ®Google Scholar
• BurneyPG, HooperR. Forced vital capacity, airway obstruction and survival in a general population sample from the USA. Thorax. 2011;66(1):49–54. doi:10.1136/thx.2010.14704120980245
   PubMed Web of Science ®Google Scholar
• BurneyP, JithooA, KatoB, et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty–a BOLD analysis. Thorax. 2014;69(5):465–473. doi:10.1136/thoraxjnl-2013-20446024353008
   PubMed Web of Science ®Google Scholar
• WeissST, SegalMR, SparrowD, WagerC. Relation of FEV1 and peripheral blood leukocyte count to total mortality. The normative aging study. Am J Epidemiol. 1995;142(5):493–498; discussion 499–503. doi:10.1093/oxfordjournals.aje.a117665
   Web of Science ®Google Scholar
• SinDD, ManSF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519. doi:10.1161/01.CIR.0000056767.69054.B312654609
   PubMed Web of Science ®Google Scholar
• RabeKF, HurstJR, SuissaS. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):180057. doi:10.1183/16000617.0057-201830282634
   PubMed Web of Science ®Google Scholar
• WilliamsMC, MurchisonJT, EdwardsLD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014;69(8):718–723. doi:10.1136/thoraxjnl-2012-20315124473329
   PubMed Web of Science ®Google Scholar
• CalverleyPM, TetzlaffK, DusserD, et al. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. Int J Chron Obstruct Pulmon Dis. 2017;12:3391–3405. doi:10.2147/COPD.S14581429238184
   PubMed Web of Science ®Google Scholar
• HoogendoornM, FeenstraTL, BolandM, et al. Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. Int J Chron Obstruct Pulmon Dis. 2017;12:3183–3194. doi:10.2147/COPD.S14237829138546
   PubMed Web of Science ®Google Scholar
• FriedmanGD, KlatskyAL, SiegelaubAB. Lung function and risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1976;294(20):1071–1075. doi:10.1056/NEJM1976051329420011256523
   PubMed Web of Science ®Google Scholar
• SinDD, WuL, ManSF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–1959. doi:10.1378/chest.127.6.195215947307
   PubMed Web of Science ®Google Scholar
• SpeizerFE, FayME, DockeryDW, FerrisBG Jr. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis. 1989;140(3 Pt 2):S49–S55. doi:10.1164/ajrccm/140.3_Pt_2.S492782760
   PubMed Web of Science ®Google Scholar
• DuongM, IslamS, RangarajanS, et al. Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. Lancet Glob Health. 2019;7(5):e613–e623. doi:10.1016/S2214-109X(19)30070-131000131
   PubMed Web of Science ®Google Scholar
• TockmanMS, PearsonJD, FlegJL, et al. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med. 1995;151(2 Pt 1):390–398. doi:10.1164/ajrccm.151.2.78421977842197
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, HurstJR, SmithCJ, HubbardRB, WedzichaJA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091–1097. doi:10.1378/chest.09-202920022970
   PubMed Web of Science ®Google Scholar
• KunisakiKM, DransfieldMT, AndersonJA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–57. doi:10.1164/rccm.201711-2239OC29442524
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonJ, BrookRD, et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41(5):1017–1022. doi:10.1183/09031936.0008731223018908
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonJA, BrookRD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826. doi:10.1016/S0140-6736(16)30069-127203508
   PubMed Web of Science ®Google Scholar
• MillerMR, HankinsonJ, BrusascoV, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
   PubMed Web of Science ®Google Scholar
• MastersRK, ReitherEN, PowersDA, YangYC, BurgerAE, LinkBG. The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. Am J Public Health. 2013;103(10):1895–1901. doi:10.2105/AJPH.2013.30137923948004
   PubMed Web of Science ®Google Scholar
• MullerovaH, MaselliDJ, LocantoreN, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007. doi:10.1378/chest.14-065525356881
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• BarnesPJ, BurneyPG, SilvermanEK, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076. doi:10.1038/nrdp.2015.7627189863
   PubMed Web of Science ®Google Scholar
• AgustiA, EdwardsLD, RennardSI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483. doi:10.1371/journal.pone.003748322624038
   PubMed Web of Science ®Google Scholar
• CelliBR, AndersonJA, BrookR, et al. Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respir Res. 2019;6(1):e000431. doi:10.1136/bmjresp-2019-000431
   PubMed Web of Science ®Google Scholar